Bulletin
Investor Alert

Tilray Inc. Cl 2

NAS: TLRY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 30, 2021, 7:59 p.m.

/zigman2/quotes/209129655/composite

$

14.64

Change

+0.03 +0.21%

Volume

Volume 370,707

Quotes are delayed by 20 min

/zigman2/quotes/209129655/composite

Previous close

$ 15.42

$ 14.61

Change

-0.81 -5.25%

Day low

Day high

$14.42

$15.51

Open

52 week low

52 week high

$4.41

$67.00

Open

Company Description

Tilray, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research, cultivation, processing, and distribution of cannabis products worldwide. Its products...

Tilray, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research, cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in New York, NY.

Valuation

Price to Sales Ratio

4.95

Price to Book Ratio

3.50

Enterprise Value to Sales

5.67

Total Debt to Enterprise Value

0.29

Efficiency

Revenue/Employee

204,351.00

Income Per Employee

-263,178.00

Receivables Turnover

5.00

Total Asset Turnover

0.23

Liquidity

Current Ratio

1.91

Quick Ratio

1.40

Cash Ratio

1.22

Profitability

Gross Margin

5.45

Operating Margin

-60.49

Pretax Margin

-128.61

Net Margin

-128.79

Return on Assets

-29.43

Return on Equity

-82.25

Return on Total Capital

-17.33

Return on Invested Capital

-37.10

Capital Structure

Total Debt to Total Equity

91.28

Total Debt to Total Capital

47.72

Total Debt to Total Assets

36.08

Long-Term Debt to Equity

90.10

Long-Term Debt to Total Capital

47.10

Officers and Executives

Name Age Officer Since Title
Mr. Irwin David Simon 61 2021 Chairman & Chief Executive Officer
Mr. Carl A. Merton - 2021 Chief Financial Officer
Mr. Lloyd Brathwaite - 2021 Chief Information Officer
Dr. Joshua Eades - 2014 Chief Science Officer
Dr. Catherine Jacobson - 2018 Vice President-Regulatory & Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/16/2021 Brendan Kennedy
Director
300,000   Disposition at $14.04 per share. 4,212,000
07/15/2021 Brendan Kennedy
Director
76,289   Disposition at $15.18 per share. 1,158,067
07/15/2021 Brendan Kennedy
Director
223,711   Disposition at $14.5 per share. 3,243,809
06/18/2021 Brendan Kennedy
Director
400,000   Disposition at $17.19 per share. 6,876,000
06/17/2021 Brendan Kennedy
Director
400,000   Disposition at $17.97 per share. 7,188,000
06/03/2021 James R. Meiers
Head of Canada
23,826   Disposition at $19.64 per share. 467,942
06/01/2021 Irwin David Simon
President and CEO; Director
120,824   Derivative/Non-derivative trans. at $16.98 per share. 2,051,591
06/01/2021 Irwin David Simon
President and CEO; Director
36,248   Derivative/Non-derivative trans. at $16.98 per share. 615,491
06/01/2021 Irwin David Simon
President and CEO; Director
242,277   Derivative/Non-derivative trans. at $0 per share. 0
06/01/2021 Irwin David Simon
President and CEO; Director
72,683   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Carl A. Merton
Chief Financial Officer
36,779   Derivative/Non-derivative trans. at $13.93 per share. 512,331
05/14/2021 Carl A. Merton
Chief Financial Officer
41,500   Derivative/Non-derivative trans. at $11.56 per share. 479,740
05/12/2021 Irwin David Simon
President and CEO; Director
13,787   Derivative/Non-derivative trans. at $14.53 per share. 200,325
05/12/2021 Irwin David Simon
President and CEO; Director
11,066   Derivative/Non-derivative trans. at $14.53 per share. 160,788
05/12/2021 Irwin David Simon
President and CEO; Director
129,187   Derivative/Non-derivative trans. at $14.53 per share. 1,877,087
05/12/2021 Irwin David Simon
President and CEO; Director
11,066   Derivative/Non-derivative trans. at $14.53 per share. 160,788
05/12/2021 Irwin David Simon
President and CEO; Director
38,756   Derivative/Non-derivative trans. at $14.53 per share. 563,124
05/12/2021 Irwin David Simon
President and CEO; Director
38,760   Derivative/Non-derivative trans. at $14.53 per share. 563,182
05/12/2021 James R. Meiers
Head of Canada
7,299   Derivative/Non-derivative trans. at $14.53 per share. 106,054
05/12/2021 Denise Menikheim Faltischek
Chief Strategy Officer
10,608   Derivative/Non-derivative trans. at $14.53 per share. 154,134
05/12/2021 Carl A. Merton
Chief Financial Officer
89,000   Disposition at $14.82 per share. 1,318,980
05/12/2021 Irwin David Simon
President and CEO; Director
25,852   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Irwin David Simon
President and CEO; Director
20,750   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Irwin David Simon
President and CEO; Director
242,240   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Irwin David Simon
President and CEO; Director
20,750   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Irwin David Simon
President and CEO; Director
72,672   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Irwin David Simon
President and CEO; Director
72,678   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 James R. Meiers
Head of Canada
31,125   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2021 Denise Menikheim Faltischek
Chief Strategy Officer
31,125   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2021 Jon Levin
Chief Operating Officer
29,741   Derivative/Non-derivative trans. at $16.99 per share. 505,299
05/03/2021 Jon Levin
Chief Operating Officer
15,277   Derivative/Non-derivative trans. at $16.99 per share. 259,556
05/03/2021 Jon Levin
Chief Operating Officer
34,932   Derivative/Non-derivative trans. at $16.99 per share. 593,494
04/30/2021 Brendan Kennedy
Director
76,000   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Brendan Kennedy
Director
73,954   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Michael B. Auerbach
Director
52,622   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Michael Kruteck
Chief Financial Officer
53,192   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Michael Kruteck
Chief Financial Officer
66,640   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Michael Kruteck
Chief Financial Officer
29,143   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Jon Levin
Chief Operating Officer
56,738   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Jon Levin
Chief Operating Officer
29,143   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Jon Levin
Chief Operating Officer
66,640   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Rebekah Dopp
Director
37,310   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Christine Thompson St. Clare
Director
37,310   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Soren W. Schroder
Director
35,817   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Carl A. Merton
Chief Financial Officer
258,105   Award at $0 per share. 0
04/30/2021 Renah A. Persofsky
Director
15,639   Award at $0 per share. 0
04/30/2021 Walter E. Robb
Director
4,190   Award at $0 per share. 0
04/30/2021 Thomas Looney
Director
628   Award at $0 per share. 0
04/30/2021 Michael Kruteck
Chief Financial Officer
25,796   Derivative/Non-derivative trans. at $16.99 per share. 438,274
04/30/2021 Michael Kruteck
Chief Financial Officer
32,318   Derivative/Non-derivative trans. at $16.99 per share. 549,082
04/30/2021 Michael Kruteck
Chief Financial Officer
14,134   Derivative/Non-derivative trans. at $16.99 per share. 240,136
/news/latest/company/us/tlry

MarketWatch News on TLRY

  1. Tilray stock price target cut to $14 from $16 at Stifel Nicolaus

    7:21 a.m. July 30, 2021

    - Tomi Kilgore

  2. Tilray Stock Is Up After Surprise Quarterly Profit

    11:35 a.m. July 28, 2021

    - Connor Smith

  3. Tilray CEO asks shareholders to approve additional share issuance to fund growth initiatives

    7:05 a.m. June 29, 2021

    - Ciara Linnane

  4. Tilray rated overweight at Cantor after Aphria merger closes

    7:11 a.m. June 4, 2021

    - Ciara Linnane

  5. Stocks Close Down on Fed's Decision to Sell Corporate Bonds

    4:33 p.m. June 3, 2021

    - Steve Goldstein

  6. Elastic Pops, Tilray Rises, and Stocks Are Down

    9:10 a.m. June 3, 2021

    - Jacob Sonenshine

  7. Cannabis stocks rally after Amazon endorses legalization

    4:28 p.m. June 2, 2021

    - Tomi Kilgore

  8. Marijuana Grower Gets Stoked by Key Upgrade

    4:12 p.m. May 25, 2021

    - Connor Smith

  9. Loading more headlines...
/news/nonmarketwatch/company/us/tlry

Other News on TLRY

  1. 2 Trends for All Pot Stock Investors to Follow

    4:00 p.m. July 31, 2021

    - Motley Fool

  2. 3 Cannabis Growth Stocks You Don't Want to Miss in August

    9:21 a.m. July 31, 2021

    - Motley Fool

  3. Why Charlotte's Web Holdings Popped Then Flopped Today

    5:52 p.m. July 30, 2021

    - Motley Fool

  4. Seeking Alpha Catalyst Watch

    3:30 p.m. July 30, 2021

    - Seeking Alpha

  5. Why Tilray Is Trouncing the Market This Week

    2:48 p.m. July 30, 2021

    - Motley Fool

  6. Is Tilray Stock a Buy After Its Surprising Q4 Profit?

    5:55 a.m. July 30, 2021

    - Motley Fool

  7. Why Hexo, Tilray, OrganiGram, and Sundial Stocks Are Wilting

    2:37 p.m. July 29, 2021

    - Motley Fool

  8. Tilray, Inc. 2021 Q4 - Results - Earnings Call Presentation

    9:48 a.m. July 29, 2021

    - Seeking Alpha

  9. Tilray: Same Tired Story

    12:37 a.m. July 29, 2021

    - Seeking Alpha

  10. Tilray, Inc. (TLRY) Q4 2021 Earnings Call Transcript

    8:32 p.m. July 28, 2021

    - Motley Fool

  11. Why Cannabis Giant Tilray (TLRY) Skyrocketed Today

    6:07 p.m. July 28, 2021

    - Zacks.com

  12. 5 Top Stock Trades for Thursday: F, SHOP, MSFT, PFE, TLRY

    5:41 p.m. July 28, 2021

    - InvestorPlace.com

  13. What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

    5:09 p.m. July 28, 2021

    - InvestorPlace.com

  14. 10-K: TILRAY, INC.

    4:46 p.m. July 28, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  15. Loading more headlines...

At a Glance

Tilray, Inc.

655 Madison Avenue

19th floor

New York, New York 10065

Phone

1 5193228800

Industry

Farming

Sector

Agriculture

Fiscal Year-end

12/2021

Revenue

$210.48M

Net Income

$-271.07M

2020 Sales Growth

26.1%

Employees

1,030

/news/pressrelease/company/us/tlry

Press Releases on TLRY

  1. Good Stocks To Buy Today? 5 Leisure Stocks In Focus

    2:42 p.m. July 28, 2021

    - StockMarket.com

  2. Tilray, Inc. Reports 2021 Fiscal Year and Fourth Quarter Results

    7:00 a.m. July 28, 2021

    - BusinessWire - BZX

  3. Best Marijuana Stocks To Buy In 2021? 4 For Your Watchlist

    10:30 p.m. July 20, 2021

    - StockMarket.com

  4. Top Weed Stocks To Watch Today? 3 For Your Watchlist

    9:03 a.m. July 16, 2021

    - StockMarket.com

  5. High Tide and Halo Announce Closing of Sale of KushBar Assets to Halo

    7:41 a.m. July 15, 2021

    - PR Newswire - PRF

  6. Loading more headlines...
Link to MarketWatch's Slice.